Articles

Vigilant Biosciences Commences Studies of Oral Cancer Test June 26, 2017 Vigilant Biosciences Inc, Fort Lauderdale, Fla, has launched patient enrollment for clinical studies of its OncAlert point-of-care qualitative assay in support of its premarket regulatory submission to FDA. Vigilant Biosciences’ initial clinical study is designed to validate performance and evaluate implementation of the OncAlert

Fort Lauderdale biotech firm gets federal grant for oral cancer study June 14, 2017 Fort Lauderdale-based Vigilant Biosciences, which has developed dental and lab toolkits for early detection of oral cancer, has been awarded part of a multi-million dollar grant for a study from the National Institutes of Health. The five-year study will enroll 300

Tests May Detect Oral Cancer Earlier June 2, 2017 Oral and throat cancers can be life-threatening, and their frequency seems to be increasing. Now, two tests that are simple, painless and noninvasive can often detect them at very early stages when they can often be treated successfully. Both were developed here in South Florida. When

Vigilant Biosciences Launches Clinical Studies of Oral Cancer Assay May 12, 2017 Vigilant Biosciences has launched patient enrollment for clinical studies of its OncAlert point-of-care qualitative assay in support of its registration submission to the Food and Drug Administration (FDA). The clinical studies are designed to validate the performance and evaluate the implementation of the OncAlert

Clinical Lab Trends for 2017 May 12, 2017 Oral cancer – including cancers of the mouth and throat – is an area that is attracting new attention from the diagnostic community – this time with the help of dentists. New, promising technologies are making it easier for dental and medical professionals to detect oral cancer

Oral Cancer Tests May 12, 2017 The OncAlert oral cancer product line from Vigilant Biosciences Inc., Fort Lauderdale, Fla, includes the OncAlert oral cancer rapid test and the OncAlert oral cancer lab test, available in countries accepting CE mark. The tests are based on technology that accurately measures CD44, a tumor-initiating and stem cell-associated biomarker,

Number To Know…1,000 May 12, 2017 Vigilant Biosciences has initiated a US FDA clinical study, with plans to recruit up to 1,000 patients, of its OncAlert point-of-care oral cancer risk assessment test. Source: Medtech Insight Back to News

The Word of Mouth on Oral Cancer May 3, 2017 Nearly 50,000 people are diagnosed with oral cancer in the U.S. each year—and that number continues to grow, particularly among certain segments of the population. While all adults should be screened for oral cancer annually, those who smoke or use smokeless tobacco, and/or consume alcohol

Survey Reports That Patients Want Oral Cancer Screenings and Education April 19, 2017 More than 49,750 people in the United States will be diagnosed with oral cancer this year, according to Vigilant Biosciences. Yet 62% of adults in the US know very little or nothing at all about the disease—including cancer of the oral cavity, tongue,

4.0% of American Adults Carry High-Risk Oral HPV April 17, 2017 While tobacco and alcohol consumption remain the chief causes of oral cancer, the number of cases caused by the human papillomavirus (HPV) have been increasing. In fact, the Centers of Disease Control and Prevention (CDC) reports that 4.0% of all adults in the United